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ADULT UROLOGY
ELSEVIER
URODYNAMIC AND CLINICAL EFFECTS OF TERAZOSIN 
THERAPY IN SYMPTOMATIC PATIENTS WITH 
AND WITHOUT BLADDER OUTLET OBSTRUCTION: 
A STRATIFIED ANALYSIS
WIM P. J. WITJES, PETER F. W. M. ROSIER, CHRISTINE T. M. CARIS, FRANS M. J. DEBRUYNE,
AND JEAN J. M. C. H. DE l a  ROSETTE
ABSTRACT
Objectives, To evaluate clinical and urodynamic changes in patients with and without bladder outlet obstruc­
tion [BOO] and to compare the. clinical and urodynamic results of terazosin treatment between patients with 
and without BOO.
Methods, In a prospective study, 97 patients who completed a full screening program including urodynamic 
investigation with pressure-flow study analysis started treatment with terazosin. A total of 60 patients com­
pleted 6 months of treatment and were re-evaluated with International Prostate Symptom Scores (IPSS), 
uroflowmetry, and urodynamic investigation with pressure-flow study analysis. Patients were stratified using 
the linear passive urethral resistance relation (lin-PURR) classification according to Sdhafer. Patients with a 
!in-PURR of 3 or more were classified as patients with BOO and patients with a lin-PURR of 2 or less were 
classified as patients without BOO. The clinical and urodynamic changes within and between the groups with 
and without BOO were evaluated.
Results. Terazosin resulted in significant symptomatic relief (9 points on the IPSS scale; P <0.01) and a 
significant improvement of free urinary flow (3.0 mL/s; P <0.01). In patients with BOO, a statistically signif­
icant improvement of all urodynamic obstruction variables (P <0.01) was shown. In patients without BOO, 
a significant improvement of free urinary flow (4.4 mL/s; P <0.01), a statistically significantly improved 
bladder capacity (increase of 70 mL; P = 0.01), and no statistically significant changes in urodynamic ob­
struction variables (P >0.05) were shown. Patients with a hypoactive detrusor were more prone to early 
dropout. When comparing the changes of symptoms (P = 0.89), quality of life (P = 0.85), and the number 
of patients with improvements of free uroflow of at least 30% (P = 0.15), there appeared to be no significant 
difference between the groups with and without BOO.
Conclusions. Although there is a statistically significant difference in urodynamic response to terazosin treat­
ment between patients with and without BOO, we cannot recommend the use of pressure-flow studies in the 
selection of patients for terazosin treatment because the clinical results of treatment appear not to be sig­
nificantly different between patients with and without BOO. It seems more useful, and certainly less expensive 
and less invasive, to start alpha^blocker therapy if, on clinical grounds, the urologist considers the patient 
to be a candidate for alphar blocker therapy, and to continue therapy in those who respond. Copyright 
1997 by Elsevier Science Inc. UROLOGY 49: 197-206, 1997.
L ower urinary tract symptoms (LUTS) in elderly 
men are traditionally labeled as prostatism. 
The term suggests that the enlarged prostate gland,
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causing infravesical bladder outlet obstruction 
(BOO), is exclusively responsible for the LUTS. 
However, benign prostatic hyperplasia (BPH) is a 
histologic diagnosis, and LUTS are not necessarily 
related to urodynamically proven BOO or histo­
logically proven BPH.1,2 LUTS have been shown to 
be prevalent in an age-matched female population, 
indicating that the prostate is not required for the 
occurrence of these symptoms.3 It has also been 
recognized that LUTS are related to detrusor in­
stability or detrusor underactivity in a large per-
*
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centage of elderly men.4,5 Obviously, the patho­
physiology of LUTS is not always clear without an 
advanced urodynamic pressure-flow study inves­
tigation. Urodynamic pressure-flow study investi­
gation is the reference standard to quantify the 
grade of BOO in elderly men with LUTS.6 Precise 
grading of obstruction is becoming increasingly 
important in the evaluation and comparison of 
new therapeutic options in the treatment of pa­
tients with LUTS.
Because it is known that alphai-adrenoreceptors 
are predominantly present in the bladder neck and 
prostate smooth muscle, alphai-blocking agents 
have successfully been used to relieve symptoms 
in patients with LUTS,7"9 Terazosin is a long-act­
ing alphar selective blocking agent originally used 
in the treatment of patients with hypertension. 
The effects of terazosin on symptom scores and 
urinary flow rates in large groups of patients with 
LUTS have been well documented.8,9 These studies 
indicate that approximately 60% of patients re­
spond well on treatment with terazosin. So far, it 
is unknown if it is possible to predict a good re­
sponse on alphar blocker treatment in the individ­
ual patient. Consequently, selection of patients 
who should be treated with an alphai-blocker or 
one of the other treatment modalities is still not 
based on scientific grounds. Earlier studies indi­
cated that inclusion of urodynamic pressure-flow 
data in the preoperative evaluation may improve 
the overall clinical results, as does an indication 
for transurethral resection of the prostate.5,10,11 
Jensen11 showed that symptomatic patients with­
out BOO have a higher likelihood of subjective 
postoperative treatment failure when compared 
with symptomatic patients with BOO. It is un­
known if a stratification based on the grade of BOO 
has any predictive value for patients who are 
treated with an alphai-selective blocking agent. In 
our study, we investigated possible differences in 
treatment outcome between patients with and pa­
tients without BOO who were treated with tera­
zosin.
PATIENTS AND METHODS
Id 1992, we started a prospective study to evaluate the out­
come of therapy in patients with LUTS treated with terazosin. 
Between September 1992 and October 1994, all patients were 
evaluated at baseline by medical history, International Pros­
tate Symptom Score (IPSS), prostate-specific antigen analysis, 
physical examination including digital rectal examination, ul­
trasonographic examination of the prostate, and free urinary 
flowmetry with subsequent ultrasonographic measurement of 
residual urinary volume. Prostate-specific antigen was deter­
mined using the Tandem-E PSA assay (Hybritech, San Diego, 
Calif). Prostate volume was calculated using the planimetric 
method with a Kretz Combison 330 ultrasound scanner and 
a multiplane 3-D rectal transducer (VRW 177AK). For free 
urinary flowmetry, the Dantec Urodyn 1000 flowmeter was 
used. For evaluation of the voiding efficiency, the voided per­
centage (the relative amount of bladder contents that was ex­
pelled during micturition), was calculated. All patients were 
considered neurologically normal, based on history, symp­
toms, and physical examination (no motor, sensory or reflex 
deficits). Patients in whom a prostatic carcinoma or other dis­
ease beyond the prostate could be expected, which could pos­
sibly influence their LUTS (for example, urethral stricture or 
bladder neck contracture), were evaluated more extensively 
first (by prostate biopsy or urethrocystoscopy) and excluded 
if these diseases were confirmed. Excluded were patients pre­
viously treated with transurethral (laser) resection of the pros­
tate, transurethral microwave thermo therapy, or 5alpha-re- 
ductase inhibitors. Patients treated with alpha-blockers within
4 weeks before the baseline pressure-flow study was per­
formed were also excluded. There were no explicit urody­
namic pressure-flow study selection criteria. After the clinical 
diagnosis was established, patients were informed about the 
treatment options. When the patient experienced moderate 
symptoms or the patient was bothered by his symptoms, ter­
azosin treatment was recommended in addition to other min­
imally invasive therapies. Patients started treatment with an 
increasing dose, to a maximum of 10 mg/day terazosin at 6 
weeks of treatment, administered at bedtime. Every patient’s 
dose was titrated up to 10 mg, but patients not tolerating the 
10-mg dose had their dosage decreased to 5 mg. Urodynamic 
pressure-flow studies before and after 6 months of treatment 
with terazosin were used to evaluate urodynamic changes. 
Urinalysis and culture were negative at the time of pressure- 
flow studies. After 6 months of treatment, patients were re- 
evaluated both clinically and urodynamically.
Urodynamic pressure-flow studies were performed with an 
8F transurethral lumen catheter equipped with an intravesical 
micro tip pressure sensor for bladder-pressure recording. Ab­
dominal pressure was recorded intrarectally with an 8F mi­
crotip sensor catheter (MTC, Drager, Best, Netherlands). Be­
fore cystometry, the bladder was emptied through the lumen 
of the transurethral catheter. The bladder was filled with 20°C 
water at a rate of 50 mL/min, with the patient in supine po­
sition. To ensure a reliable micturition diary, free uroflow- 
metry, and residual urine, care was taken to fill the bladder 
until the maximum bladder capacity was reached. Filling was 
stopped when the patient expressed a very strong urge to void. 
Commercially available equipment (UD 2000, MMS, En­
schede, Netherlands) was used to record the pressure and flow 
data. Digitally stored data were translated to a urodynamic 
analysis computer program developed at our own department. 
This program provides a half automatic pressure-flow study 
analysis with passive urethral resistance relation (PURR) and 
urethral resistance factor (URA).
To provide an objective and precise grading of obstruction, 
pressure-flow graphs were fitted with a PURR curve at the 
lowest pressure part of the graph.12 The minimal urethral 
opening pressure during micturition (Pvoidmin) and theoreti­
cal cross-sectional urethral lumen (Atheo) were calculated au­
tomatically on the basis of these manually adjusted PURR 
curves,12 The pressure at maximum flow during the urody­
namic investigation (PdetQmax) was recorded. Correction for 
flow artifacts was performed when necessary. URA was deter­
mined by fitting the pressure-flow plot at the point of maxi­
mum flow (at P^Qmax). URA was used to classify patients 
on a continuous, one-parameter scale of obstruction.13 We 
also added a nonparametric analysis of obstruction with clin­
ical classes according to the linear PURR (lin-PURR) pressure- 
flow nomogram.14 The lin-PURR was determined by drawing 
a straight line between the PdctQmax and the Pvoidmin points 
on the pressure-flow curve. The position of this line defined 
the outlet condition in a simple way and allowed classification 
of the severity of BOO. The following urodynamic variables 
were analyzed from free flowmetry: free Qmax; free voided
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TABLE I. Mean baseline characteristics of 97 patients included in the study (standard deviation
in parentheses) *
Whole group 
(n = 97)
Patients Without 
BOO (lin-PURR <3) 
{n - 53)
Patients with BOO 
(lin-PURR ^3)
(n = 44)
P  value 
Between 
Croups
Age (years) 62 (9) 61 (9) 63 (8) 0.31
Prostate-specific antigen (ng/mL) 3.8 (3.8) 3.4 (3.5) 4.5 (4.1) 0.29
Prostate volume (cc) 38 (18) 34 (16) 42 (20) 0.06
IPSS 19.1 (5.9) 18.9 (5.8) 19.8 (5.8) 0.47
IPSS quality of life score 4.1 (1.2) 4.0 (1.2) 4.2 (1.2) 0.70
Free voided volume (mL) 265 (136) 296 (154) 231 (100) 0.06
Free Qmax (mL/s) 10.5 (5.5) 11.6 (6.5) 9.0 (3.7) <0.01
Free residual volume (mL) 73 (120) 58 (86) 94 (154) 0.06
Free voided percentage (%) 81 (18) 85(15) 77 (20) 0.02
Bladder capacity (mL) 424(134) 437 (144) 400 (1 18) 0.28
Urod Qmax (mL/s) 7.7 (4.1) 9.4 (4.5) 5.5 (2.0) <0.01
Urod residual volume (mL) 113 (157) 79 (146) 142 (147) <0.01
Urod voided percentage (%) 77 (28) 85 (25) 69 (26) <0.01
PdetQmax (cm H20) 57.5 (29.8) 39.8 (16.2) 80.5 (27.6) <0.01
Pvoidmm (cm H20) 29.1 (18.1) 18.4 (9.2) 42.8 (17.7) <0.01
A«,« (mm2) 3.7 (2.7) 4.9 (3.1) 2.1 (0.8) <0.01
URA (cm H20) 35.2 (19.3) 22.5 (7.7) 51.7 (17.3) <0.01
lin-PURR 2.4 (1.5) 1.3 (0.7) 3.9 (0.9) <0.01
K e y : — theoretical cross-sectional urethral lumen; BOO =  bladder outlet obstruction; IPSS =  Jn iem trtiijn a l Prostate Symptom Score; lin-PURR ~  linear passive 
uretheral resistance relation; P,tetQmax = detrusor pressure at maximum JIow; Pvoid„lin =  mmiinal urethral opening pressure (hiring iniciiiriiion; Qmax =  maximum Jloiv; 
URA = urethral resistance factor; urod Qmax = maximum flow during urodynamic mvesiigniicm; urod residual volume =  residual vohanc after urodynamic pressurc-jlow 
study; urod voided percentage ~  voided percentage during pressure-jlow study.
* P value indicates statistically signi/jcant difference (P <0.05) between the baseline characteristics of the groups with and without bladder outlet obatruction
volume; residual volume after free flowmetry; and free voided 
percentage. Bladder capacity was analyzed from cystometry* 
Finally, the following were analyzed from pressure-flow 
study: maximum flow during urodynamic investigation (urod 
Qmax), PLlelQmax, Pvoidniin, Alheo, URA, residual volume after 
urodynamic pressure-ilow study (urod residual volume), and 
voided percentage during pressure-flow study (urod voided 
percentage) for the whole group of patients and for subgroups 
of patients who were categorized as patients with BOO (lin- 
PURR of 3 or more) and patients categorized as patients with­
out BOO (lin-PURR less than 3).15
All statistical tests were two-sided and carried out at the 
5% significance level. For numerical variables (such as symp­
tom scores, quality-of-life scores, free flow parameters, and 
urodynamic parameters), within-treatment changes were as­
sessed using the paired £ test or the Wilcoxon matched-pairs 
signed-ranks test; between-treatment group changes were as­
sessed using the t test for independent samples or the Mann- 
Whitney U test. The number of patients with an increase of 
voided volume of 50 mL or greater and with an improvement 
of Qmax of 10% or more from baseline in the groups with 
and without BOO were compared using the chi-square test.
RESULTS
From September 1992 to October 1994, 97 pa­
tients started treatment with terazosin. The base­
line characteristics of 97 patients— and for sub­
groups with and without BOO— who were 
included in the study are indicated in Table I. This 
table indicates that patients without BOO had, in 
addition to significantly different urodynamic vari­
ables, a significant higher free Qmax and a signif­
icantly higher free voided percentage.
Twenty-eight patients (29%) stopped terazosin 
treatment before the evaluation at 6 months 
because of side effects (n =  13), no response to 
therapy (n =  12), or symptoms improving 
“spontaneously” (n = 3). The most frequent treat­
ment-related side effects were mild headache, diz­
ziness, and asthenia. Usually, these side effects 
were mild and transient. Of the 13 patients who 
experienced side effects, 9 stopped treatment be­
cause of treatment-related side effects: dizziness (n 
= 2), asthenia (n — 4), palpitations (n = 1), pe­
ripheral edema (n = 1), and paresthesia (n = 1). 
Dyspnea (n =  2), cardiac arrhythmia (n = 1), and 
visual disturbances (n = 1) were the reasons why 
the 4 other patients who experienced side effects 
stopped treatment; these events were not consid­
ered to be treatment related. Nine other patients 
were not available at 6 months because they were 
lost to follow-up (n == 4) or they refused their sec­
ond clinical and urodynamic pressure-flow study 
evaluation (n = 5). Sixty patients, of whom 30 
(50%) were classified as patients with BOO, were 
evaluated clinically and urodynamically before 
and after 6 months (median 28 months; range 17 
to 45 weeks) of treatment.
The mean variables listed in Table I were com­
pared between the group that continued taking 
terazosin for 6 months and the group that stopped 
taking terazosin before 6 months. Patients who 
stopped terazosin before 6 months were statisti-
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cally significantly younger (mean age ± SD 58 ± 
9 years) when compared with patients who con­
tinued taking terazosin up to 6 months (64 ±  8 
years; P <0.01). The mean bladder capacity in 
those who discontinued terazosin was higher (458 
± 1 2 5  mL) when compared with those who con­
tinued treatment up to month 6 (403 ±  136 mL; 
P = 0.03). When comparing the mean Pvoidmin 
(23.3 ± 15 versus 32.3 ±  18.8 cm H20; P =  0.01), 
the mean URA (29.3 ±  14.1 versus 38.6 ± 21.1 
cm H20; P = 0.04), and the mean lin-PURR cat­
egory (1.9 ± 1.4 versus 2.7 ±  1.5; P = 0.02) be­
tween those who stopped terazosin treatment and 
those who continued it for 6 months, respectively, 
the mean values of those who stopped were sig­
nificantly smaller, indicating that patients without 
BOO had a higher likelihood of stopping terazosin 
for various reasons before 6 months.
Table II outlines the mean symptom scores and 
mean urodynamic variables at baseline and after 6 
months of treatment of the 60 patients who com­
pleted terazosin treatment for 6 months; the pa­
tients are divided into two subgroups, those with 
and without BOO. Also indicated in this table is 
the comparison of the changes in these variables 
between the groups with and without BOO. Mean 
total IPSS improved significantly in both groups: 
from 19.7 to 10.6 in the group without BOO and 
from 20.1 to 11.1 in the group with BOO (for both 
groups, P <0.01). The mean IPSS quality-of-life 
score improved significantly in both groups: from
4.1 to 2.0 in the group without BOO and from 4.1 
to 2.3 in the group with BOO (for both groups, P 
<0.01). The mean symptom and quality-of-life- 
related changes between the groups without and 
with BOO were not significantly different (P = 
0.89 and P = 0.85, respectively). In patients with­
out BOO, mean free Qmax improved significantly 
by 4.4 mI7s (P <0.01), mean free voided volume 
increased by 24 mL (P = 0.52), and mean free 
residual volume did not change significantly (P = 
0.24). In the patients with BOO, mean free Qmax 
improved significantly by 1.6 mL/s (P =  0.04), 
mean free voided volume decreased by 32 mL (P 
= 0.15), and mean free residual volume decreased 
significantly from 110 to 59 mL (P -  0.03). The
mean change of free Qmax was significantly higher 
in the group without BOO when compared with 
the group with BOO (P = 0.01). This could have 
been related to an increase of voided volume of 24 
mL in the group without BOO and a decrease of 
voided volume of 32 mL in the group with BOO. 
The statistically significant difference in the 
change of free Qmax between the groups with and 
without BOO was evaluated further. Small im­
provements in free Qmax (10% or more from base­
line) were found significantly more frequently in 
patients without BOO (77%) than in patients with
BOO (48%) (P = 0.02). This higher number of 
patients with a small improvement of free Qmax 
could be related to an increase in free voided vol­
ume in patients without BOO. Forty-seven percent 
of the patients without BOO had an increase of free 
voided volume of at least 50 mL, whereas of those 
in the group with BOO, only 14% had an increase 
of free voided volume of 50 mL or greater (P 
<0.01). When comparing the number of patients 
with larger improvements of free Qmax (30% or 
50% or more from baseline), there were no signif­
icant differences between the two groups. Sixty per­
cent of the patients without BOO and 41% of the 
patients with BOO had an increase of free Qmax of 
30% or more from baseline (P = 0.15), and 43% 
and 34%, respectively, had an increase of free Qmax 
of 50% or more from baseline (P = 0.49). The mean 
free voided percentage improved from 85% to 91% 
in the group without BOO and from 74% to 82% 
in the group with BOO; changes within and be­
tween these groups were not significant.
The evaluation of the pressure-flow study vari­
ables urod Qmax, PdclQmax, Pvoidmin, Atheo, URA, 
and lin-PURR in the patients with BOO revealed 
statistically significant improvements of all mean 
variables after 6 months of terazosin treatment 
(Table II). Significant changes of pressure-flow 
study variables in patients without BOO could not 
be detected, except for mean urod Qmax which 
improved significantly with 1.6 mL/s (P = 0.02). 
The mean bladder capacity in patients without 
BOO improved from 420 to 485 mL, which was 
statistically significant (P = 0.01). When evaluat­
ing the mean urodynamic changes between the 
groups with and without BOO, the changes for the 
variables urod voided percentage, PaetQmax, 
Pvoidmin, URA, and lin-PURR were significantly 
higher in the group with BOO. In Figure 1, the 
improvements of PdetQmax and total IPSS are plot­
ted for each patient who completed 6 months of 
treatment. The patients with BOO tended to have 
a larger urodynamical improvement when com­
pared with patients without BOO. However, the 
symptomatic improvement is in the same range in 
both groups.
In Table III, the mean changes in symptoms, qual­
ity of life, free uroflow variables, and urodynamic 
variables are compared between the group of pa­
tients who improved urodynamically (that is, the 
group that had a lin-PURR decrease of 1 point or 
more on the Schafer nomogram) and the group who 
did not. Only the changes in the inter-related uro­
dynamic variables PdetQmax, Pvoidmim URA, and lin- 
PURR were significantly higher in the group that 
improved urodynamically. The mean changes in 
symptoms, quality of life, and free uroflow variables 
were not significantly different between those who 
improved urodynamically and those who did not.
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TABLE II. Mean characteristics, at baseline and after 6 months of terazosin treatment, for the 
60 patients who completed the second urodynamic evaluation, divided into subgroups of patients,
with and without bladder outiet obstruction (standard deviation in parentheses) *
Total IPSS
IPSS quality-of-life score
Free voided volume (mL)
Free maximal flow rate (mL/s)
Free residual volume (mL)
Free voided percentage {%)
Bladder capacity (mL)
Urod Qmax (mL/s)
Urod residual volume (mL)
Urod voided percentage (%)
PdetQmax (cm H20)
Pvoldmin (cm H20)
Atheo (mm2)
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Patients Without BOO 
(lin-PURR <3)
(n = 50)
Baseline: 19,7 (6.4) 
Month 6: 10.6 (6.7) 
Change: 9.5 (7,1)
P value: <0.01 
Baseline: 4.1 (1.2) 
Month 6: 2.0 (1.3) 
Change: 2.0 (1.2)
P value: <0.01 
Baseline: 286 (163) 
Month 6: 311 (173) 
Change: 24 (191)
P value: 0.52 
Baseline: 11.4 (8.2) 
Month 6: 15.9 (8.2) 
Change: 4.4 (4.7)
P value; <0.01 
Baseline: 59 (99] 
Month 6: 45 (129) 
Change: 11 (63)
P value: 0.24 
Baseline; 85 (14) 
Month 6: 91 (14) 
Change: 6(15)
P value: 0.07 
Baseline: 420 (145) 
Month 6: 485 (192) 
Change: 70 (135)
P value: 0,01 
Baseline: 9.7 (5.1) 
Month 6: 1 1.3 (5.6) 
Change: 1.6 (4,6)
P value: 0.02 
Baseline: 84 (151) 
Month 6: 72 (134) 
Change; 12 (161)
P value: 0.62 
Baseline: 84 (24) 
Month 6: 88 (22) 
Change: 4 (26)
P value: 0.35 
Baseline: 42.5 (16.0) 
Month 6: 44.4 (1 9.4) 
Change: 1.9 (24.5)
P value: 0.70 
Baseline: 21.1 (9.8) 
Month 6: 19.1 (13.6) 
Change: 2.0 (1 5.6)
P value: 0.51 
Baseline: 5.3 (3.7) 
Month 6: 5,8 (3.0) 
Change: 0.5 (3.3)
P value: 0.11
Patients With BOO 
(lin-PURR ^3)
(n = 50)
Baseline: 20.1 (5.8) 
Month 6: 11.1 (5.7) 
Change: 9.7 (7.0)
P value: <0,01 
Baseline: 4.1 (1.1) 
Month 6: 2.3 (1.4) 
Change: 1.9 (1.8)
P value: <0.01 
Baseline: 219 (99) 
Month 6: 189 (70) 
Change: 32 (11 1)
P value: 0.15 
Baseline: 8,3 (2.7) 
Month 6: 9,9 (3.5) 
Change: 1.6 (3.4)
P value: 0.04 
Baseline: 110 (177) 
Month 6: 59 (85) 
Change: 53 (176)
P value; 0.03 
Baseline: 74 (22) 
Month 6; 82 (22) 
Change: 8 (22)
P value; 0.10 
Baseline: 388 (128) 
Month 6: 402 (127) 
Change: 14 (123)
P value: 0.93 
Baseline: 5.3 (2.2) 
Month 6: 7.2 (3.5) 
Change: 1.9 (2.7)
P value: <0.01 
Baseline: 158 (158) 
Month 6: 95 (114) 
Change: 64 (85) 
Pvalue: <0.01 
Baseline: 65 (28) 
Month 6: 79 (22) 
Change: 14 (19) 
Pvalue: <0.01 
Baseline: 81.6 (30.3) 
Month 6: 62.6 (29.4) 
Change: 19.0 (37.1) 
Pvalue: <0.01 
Baseline: 43.6 (19.1) 
Month 6: 29.8 (17.5) 
Change: 13.8 (22.3) 
Pvalue: <0,01 
Baseline: 2.1 (0.8) 
Month 6: 3.3 (2.0) 
Change: 1.2 (1.6)
P value: <0.01
«
P Value of the Change 
Between Groups
0.89
0.85
0.17
0.01
0.23
A
0.94
0.06
0.73
0.12
0.01
0.01
0.02
0.57
(continued)
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TABLE II. Continued
Patients Without BOO 
(lin-PURR <3)
(n = 30)
(JRA (cm HaO)
lin-PURR
Baseline: 23.7 (8.0) 
Month 6: 21.8 (10.6) 
Change: 1,9 (9.7)
P value: 0.07 
Baseline: 1A  (0.7) 
Month 6: 1.2 (1.0) 
Change: 0.3 (1.0)
P value: 0.30
Patients With BOO 
(lin-PURR >3 )  
(n = 30)
Baseline: 53.5 (19.6) 
Month 6: 37,7 (17.3) 
Change: 15.8 (15.8) 
P value: <0.01 
Baseline; 3.9 (1.0) 
Month 6: 2.8 (1.6) 
Change: 1.3 (1.2)
P value: <0.01
P Value of the Change 
Between Groups
<0.01
<0.01
Abbreviations as in Table I.
* P values in the columns regarding patients without and with bladder outlet obstruction indicate the significance of the comparison o f baseline versus month 6 within 
groups. P vdue between groups indicates the significance level o f the comparison o f the changes in the variables from baseline to month 6 between the groups with and 
u’iihcmt bladder outlet obstruction
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FIGURE 1. Urodynamic and 
symptomatic resuits for each indi­
vidual patient who completed 6 
months of terazosin therapy, la­
beled according to the biadder out­
let obstruction class, with BOO 
(solid circle) (linearpassive urethral 
resistance reiation [lin-PURR] o f 3 
or more) and without BOO (aster­
isk) (lin-PURR of less than 3). Im­
provement of detrusor pressure at 
maximum flow during urodynamic 
investigation (PdetQmax) in cm H20  
on the y-axis} defined as PdetQmax 
at baseline minus PdetOmax at 
month 6, and Improvement of total 
International Prostate Symptom 
Score (IPSS) on the x-axis, defined 
as total IPSS at baseline minus to­
tal IPSS at month 6.
After 6 months, 54 of 93 patients (58%) contin­
ued terazosin treatment. The others were treated 
with transurethral microwave thermotherapy (n = 
4), transurethral laser ablation of the prostate (n 
= 9), other medication (n = 7), or unknown pro­
cedures or medications (n = 4), or they were fol­
lowed with the watchful waiting policy (n = 15).
COMMENT
During the World Health Organization interna­
tional consultation on BPH in 1993, it was advised 
that, if obstruction is the end point of the study, pres- 
sure-flow studies before and after treatment should 
be used in the evaluation of new therapies.16 Pressure- 
flow studies enable us to investigate the relationship 
between subjective efficacy of treatment and objective 
voiding parameters. Moreover, the use of pressure- 
flow studies may help to select patients for a given
treatment; therefore, dropout and overtreatment per­
centages may decrease considerably.11,17
With respect to the efficacy of terazosin in the 
group with BOO, we showed that all mean values 
of PdetQmax, Pvoidmin, Atheo, and URA improved 
significantly after 6 months of treatment with ter­
azosin. From a theoretical viewpoint, the mecha­
nism of voiding using an alphai-adrenergic
blocker is changed toward better outlet distensi- 
bility during voiding; thus, it becomes more effi­
cient. The first effect of a decrease in outlet ob­
struction is presumably a change in the balance of 
bladder outlet and contraction toward a lower- 
pressure micturition with improved efficacy. The­
oretically, the increase in Qmax might not be as 
high as may be expected, which may be partly at­
tributed to a decrease in Pj^Qmax. More efficient 
voiding can also be shown by lower post-void re­
sidual volumes, but this could not be demon­
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TABLE III. Comparison of the changes after terazosin treatment for 6 months between the
group that improved urodynamicaiiy (Iin-PURR decrease of at least 7 point)
and the group that did not (standard deviation in parentheses)
Patients With a Iin-PURR Patients Without a Iin-PURR P  Value
Decrease > 1 {n = 35) Decrease > 1 (n = 25) Between Groups
Total IPSS 8,7 (5.2) 10.7 (8.7) 0.30
IPSS quality of life score 1.9 (1.5) 2.1 (1.5) 0.70
Free voided volume (mL) 3(141) -14 (181) 0.68
Free maximal flow rate (mL/s) 3.1 (5.0) 3.1 (3.3) 0.98
Free residual volume (mL) 48(164) 12 (71) 0.31
Free voided percentage (%) 9(21) 4(15) 0.94
Bladder capacity (mL) 29(119) 60 (147) 0.33
Urod Qmax (mL/s) 2.4(3.1) 0.9 (4.3) 0.13
Urod residual volume (mL) 55 (134) 13 (123) 0.21
Urod voided percentage (%) 12 (22) 5 (23) 0.43
PdetQmax (cm H20) 24.5 (26.7) -13.8 (27.5) <0.01
Pvoidmin (cm H20) 17.1 (18.9) -5.0 (13.3) <0.01
Atheo (mm2) 1.1 (2.6) 0.5 (2.7) 0.48
URA (cm H20) 17.2(11.8) -2.9 (9.7) <0.01
iin-PURR 1.6 (0.8) -0.3 (0.6) <0.01
Abbrcvifliions as in Tabic I.
strated by our patients; they had a low mean re­
sidual volume of 59 mL with a high standard 
deviation of 99 mL. A significantly larger Athe0, to­
gether with a significant decrease in Pvoidmin, in­
dicates that terazosin has relaxed the bladder out­
let so that more efficient voiding can occur.
In the patients without BOO, statistically signif­
icant changes of urodynamic variables could not 
be shown, except for free Qmax, urod Qmax, and 
bladder capacity. When evaluating the present 
study, we have to realize that this study is a non­
controlled one, so we have to be careful in drawing 
far-reaching conclusions with respect to efficacy. 
Exact quantification of the urodynamic effect of 
treatment is only possible with a double-blind, pla­
cebo-controlled study. This is mainly due to a 
large placebo effect that exists in patients treated 
with an alpha!-blocker such as terazosin. In a large 
randomized, double-blind study, Roehrborn et 
a l 18 showed a 7.6-point improvement in symptom 
score on the IPSS scale in the terazosin-treated 
group, whereas in patients treated with a placebo, 
symptom score improved by only 3.7 points. The 
improvements in free Qmax were an increase of
2.2 mL7s in the terazosin-treated group and an in­
crease of 0.8 mL/s in the placebo-treated group.18
At baseline, patients with BOO had a signifi­
cantly different voiding mechanism, with lower 
voided percentages and lower maximum flow rates 
when compared with the group without BOO (Ta­
ble I). Because terazosin treatment improves the 
obstruction classification, some patients will shift 
from the group with BOO to the group without 
BOO, and this could result in a favorable improve­
ment of free Qmax.
In the present study, dropout percentages were 
relatively higher than those reported in the liter­
ature. Lepor8 reported that, of 494 patients en­
rolled in a 42-month, open-label, multicenter 
study of terazosin, 213 (43%) withdrew prema­
turely; 55 (11%) because of lack of effectiveness,
96 (19%) because of adverse events, and 62 (13%) 
because of administrative reasons. It could be that 
the 38% dropout rate in the present study (37 of
97 patients dropped out before 6 months) is rela­
tively higher because we offered patients with 
moderate symptoms or patients who are bothered 
by their symptoms the choice between an alphai- 
blocker or other minimally invasive therapies. 
With a wide variety of minimally invasive treat­
ment options, patients and urologists may more 
easily change their original treatment decision, 
compared with a situation where, after alphai- 
blocker treatment, the only options are watchful 
waiting or prostatectomy.
Patients without BOO were more prone to early 
dropout for various reasons when compared with 
patients with BOO. In patients with a lin-PURR of 
0 or 1, the poor urinary stream is caused by a hy- 
poactive detrusor muscle. These patients benefit 
little from transurethral resection of the prostate.11 
It could be that the unobstructed patients are also 
less likely to benefit from alphai-blockers. This 
may be consistent with the assumption that it is 
unlikely that the detrusor function is improved by 
these drugs.
Our study design may be criticized for lack of a 
placebo control group and for potential selection 
bias. However, the mean changes of peak flow 
rates and symptom scores observed in this open-
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label study were comparable to the data from a 
randomized study.19 Earlier studies have indicated 
that the expected improvement of mean free Qmax 
after 6 months of treatment with terazosin is be­
tween 2.4 and 3.1 mL/s.8,9,18,19 In our study, the 
mean improvement of free Qmax in the total 
group of patients was 3.0 mUs. One may question 
the clinical relevance of a 3.0 mUs improvement 
of free Qmax. This study indicates that, besides the 
improved free Qmax, more variables may change 
after terazosin therapy. In the present study, unob­
structed patients had a statistically significantly in­
creased bladder capacity. Patients with BOO had a 
statistically significantly decreased residual vol­
ume. As a result of these changes, another mictu­
rition pattern may develop that could result in a 
significant improvement of the IPSS, especially 
when taking into account that the questions of the 
IPSS questionnaire are concerned with bladder 
emptying, frequency, intermittency, urgency, noc­
turia, weak stream, and hesitancy. All of these 
symptoms may improve as a result of improved 
free Qmax, bladder capacity, or residual volume.
When comparing the changes after 6 months of 
therapy between the patients with and without 
BOO, the changes in symptoms and quality of life 
were not significantly different (Table II). An im­
provement of free voided volume of 50 mL or 
more occurred significantly more frequently in the 
group without BOO. A larger voided volume in the 
group without BOO could result in a higher num­
ber of patients with slight improvements in free 
Qmax. When comparing the free voided volumes 
with the free Qmax, using the Liverpool nomo­
grams, it appeared that the values of the first void­
ing in the group without BOO— a voided volume 
of 286 mL and a free Qmax of 11.4 m u's— cor­
respond with the 5tli percentile whereas the values 
of the second voiding— a voided volume of 311 
mL and a free Qmax of 15.9 mL/s— correspond 
with the 17th percentile of the healthy males in­
vestigated.20 For the group with BOO, the values 
of the flows correspond with the 5tli and 10th per­
centile for the first and the second voiding, re­
spectively. This indicates that, despite the different 
voided volumes, the free Qmax increases, probably 
as a result of therapy. When we evaluated the 
number of patients with greater improvements in 
free Qmax, there was no significant difference be­
tween groups with and without BOO, which dem­
onstrates that, in our patients without BOO, sta­
tistically significant improvements in free Qmax 
were not confirmed by significant improvements 
of urodynamic variables. Significant changes in 
urodynamic variables were only shown in the 
group with BOO. This finding suggests that the 
way we analyze efficacy in most pharmacotherapy 
studies for BPH (that is, improvements in symp­
toms and small improvements of Qmax) does not 
depend on the urodynamic mechanism of action. 
Therefore, we cannot recommend the use of pres- 
sure-flow studies in the selection of patients for 
terazosin treatment in daily urologic practice be­
cause the changes of symptoms and quality oi life 
between the groups with and without BOO were 
not significantly different. Moreover, the number 
of patients with improvements of free uroflow of 
at least 30% appeared not to be significantly dif­
ferent between groups with and without BOO. 
Hence, it seems more useful and certainly less ex­
pensive and less invasive to start alphai-blocker 
therapy if, on clinical grounds, the urologist con­
siders the patient to be a candidate for alphai- 
blocker therapy and to continue therapy in those 
who are satisfied.
However, it is unknown what the long-lasting 
effect of BOO on the bladder is for patients who 
are satisfied with their treatment but who remain 
urodynamically obstructed. Do they have a higher 
likelihood of developing complications in the long 
term, such as obstructive nephropathy, urinary re­
tention, infection, bleeding, bladder stones, or 
other complications that adversely affect their 
well-being? Is there a difference in the probability 
of developing complications when compared with 
patients without BOO? Further follow-up and 
more prospective, well-controlled investigations 
are necessary to provide the still-lacking infor­
mation on the long-lasting effects and complica­
tions of pharmacologic treatment.
CONCLUSIONS
We have shown that a stratified analysis, based 
on the urodynamic classification of BOO, provides 
insight into the working mechanism of terazosin 
in patients with and without BOO. Patients with a 
hypoactive detrusor muscle may be more prone to 
drop out early when compared with patients who 
have a normal detrusor function. We also showed 
that after 6 months of terazosin treatment, the 
changes of symptoms and quality of life and the 
number of patients with improvements of free uro­
flow of 30% or greater appeared not to be signifi­
cantly different between the groups with and with­
out BOO, Therefore, we cannot recommend the 
use of pressure-flow studies in daily urologic prac­
tice if, on clinical grounds, the urologist considers 
the patient to be a candidate for alphai-blocker 
therapy. It seems more useful, and certainly less 
expensive and less invasive, to start terazosin ther­
apy for patients and to stop therapy in those who 
are not satisfied. In the dissatisfied patients, pres- 
sure-flow studies could be of help in selecting pa­
tients for more invasive treatments. In patients 
who are satisfied with their treatment, terazosin
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could be continued. However, because the long­
term complications of pharmacologic treatment in 
patients with BOO are not well known, we rec­
ommend to follow up these patients on a regular 
basis.
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EDITORIAL COMMENT
t
The authors have done an extensive urodynamic analysis 
of a group of men receiving terazosin therapy. A number of 
interesting points can be gleaned from this report: (1) not 
surprisingly, men with lower urinary tract symptoms have 
varying urodynamic findings; (2) the magnitude of response 
to terazosin cannot be predicted based on pretherapy pres- 
sure-flow evaluation; and, most interestingly, (3) the drop­
outs or discontinuation group tended to be younger, to have 
higher bladder capacities, and to not have bladder outlet ob­
struction (BOO),
There arc a number of methodologic questions that remain 
unresolved. Primarily, the population was highly select and 
not randomized. Although briefly noted by the authors, the 
primary concern is how many patients were screened. We 
know that 97 patients were enrolled, but how many were ex­
cluded and why? Given the enrollment period of more than
2 years, this relatively low number of patients suggests a po­
tential selection bias.
Second, the magnitude of response in this study is not con­
sistent with previously reported studies with terazosin. In pa­
tients without BOO, maximum flow (Qmax) increased 4.4 
mL/s, more than twice that reported from larger multicenter 
trials using either terazosin or other alpha-blockers such as 
doxazosin or tamsulosin. In addition, one would think that 
patients with BOO would have a greater likelihood of increas­
ing Qmax than those without BOO. In this study, the exact 
opposite occurred. Although the authors’ conjecture that this 
may be due to higher voided volumes in the group without 
BOO, the magnitude of response is still extraordinary.
Third, the dropout rate was 29% at 6 months. This also 
represents a higher rate than other reported clinical studies 
using alpha blockade. In addition, we reported that more than 
70% of patients were on alpha-blockers at 2 years.1
Pressure-fiow evaluation is an important instrument used 
in the diagnosis, management, and follow-up of urologic clis- 
orders that affect the lower urinary tract. Although the role 
of routine urodynamic evaluation in lower urinary Lract symp­
toms in men is in question, pressure-flow studies remain the 
best objective test for BOO. Various investigators have re-
* ported an imprecise relationship between subjective parame­
ters such as symptoms and urodynamic findings. In part, this 
may be secondary to different methods of performing uro­
dynamic studies among investigators, as well as defining the 
most appropriate parameters of obstruction. In this study, a
UROLOGY 49 (2), 1997 205
linear passive urethral resistance relation of less than 3 was 
considered urodynamic evidence of no obstruction. Should 
this parameter be the reference standard? Even urodynamic 
advocates cannot agree on what should be the parameter used 
to diagnose obstruction.
For urodynamics to have widespread clinical usefulness, 
parameters of measurement should (1) ideally correlate with 
symptoms; (2) delineate which patients are at risk if left un­
treated; and (3) predict the need for therapy and success of 
therapeutic options designed to alleviate outlet obstruction. 
The challenge of those who advocate pressure-flow evaluation 
prior to instituting therapy is to meet these aforementioned 
criteria successfully. In this regard, as recommended by the 
authors, it seems prudent, economical, and clinically reason­
able to institute a trial of alpha-blockade in lieu of sophisti­
cated pressure-flow evaluation.
Steven A. Kaplan, M.D, 
Columbia Presbyterian Hospital
Atchley Pavilion 
161 Fort Washington Avenue
11th Floor 
New York, NY 10032
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REPLY BY THE AUTHORS
There is no dispute that there are methodologic questions 
when comparing the results of noncontrolled studies. A large 
part of the differences between noncontrolled studies can be 
explained by selection of patients or by using other techniques 
of measurement. Our group of patients may be a specifically 
selected group of patients. In our hospital, when the patient 
experiences moderate symptoms or is bothered by his symp­
toms, treatment with an alpha i-blocker is recommended in 
addition to other minimally invasive therapies, such as trans­
urethral microwave thermo therapy or laser treatment of the 
prostate. With such a wide variety of treatment options, the 
group of patients who choose alphai-blocker treatment may 
be different when compared with the situation where the only 
other treatment options are watchful waiting and prostatec­
tomy. Furthermore, patients and urologists may more easily 
change their original treatment decision and, hence, a larger 
number of patients will drop out from the study.
In patients without bladder outlet obstruction, the magni­
tude of improvement of mean free maximum flow (4.4 mL/s) 
is higher than the previously reported 2.4 to 3.1 mlVs. How­
ever, the 95% confidence interval of this improvement indi­
cates that, in this group of patients, the true mean difference 
lies between 2.7 and 6.2 mL/s, and these values show an over­
lap with previously reported numbers. Moreover, when the 
maximum flow during urodynamic investigation was taken 
into account, the mean improvement of maximum flow was 
not significantly different between the patients with or with­
out obstruction despite a larger bladder capacity (P = 0.06) 
in patients without bladder outlet obstruction. This indicates 
that the large improvement in maximum flow in patients
without bladder outlet obstruction, as shown in our study, is 
consistent with previously reported studies.
An imprecise relationship between symptoms and urody­
namic findings was recently reported by Ezz el Din et al.1 who, 
in one center, evaluated the relationship between urodynamic 
findings and the International Prostate Symptom Score and 
specific questions in 803 patients. They concluded that these 
methods measure different aspects of the clinical condition 
that should be viewed separately in the evaluation and treat­
ment decision of the patient presenting with lower urinary 
tract symptoms. Witjes et al.2 have recently shown that uro­
dynamics and symptom scores are unable to delineate which 
patients are at risk when left untreated, Patients with severe 
obstruction on urodynamics did not worsen in the short term; 
on the contrary, they were more likely to improve than to 
deteriorate urodynamically. Symptoms in this specific group 
of patients did not change significantly, confirming the dis­
crepancy between subjective and objective data.
Because earlier studies have indicated that inclusion of 
pressure-flow data in the preoperative evaluation and patient 
selection for interventional therapies such as transurethral re­
section of the prostate and transurethral microwave thermo- 
therapy may improve the overall clinical results,3,4 it is our 
opinion that symptoms alone should not be used as the main 
indication for deciding on the appropriate minimally invasive 
or invasive treatment options.
We agree with Dr. Kaplan that, with future analyses of stud­
ies such as the ICS-'BPH* study,5 we may be able to provide 
vital information on the relative potential of symptoms and 
urodynamic and other clinical parameters to predict a favor­
able response to current and innovative treatments.
Wtm PJ. Witjes 
Peter F.W.M. Rosier 
Christine T.M. Caris 
Frans M.J. Debruyne 
Jean JM.C.H. de la Rosette
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